

Maximizing The Effectiveness of Peptide Treatments & **WHY Some Patients** Are Resistant



Brett J. Earl, M.D.



Your presence places you in an very small percentage of medical providers. Western Medicine tends to trail the 'cutting edge' of providership by 15-20 years.

- Pancreatic Endocrine Enzymatic Insufficiency
- Vitamin D
- Fish Oil
- NaCl vs. Natural Salts

83% of studies prove exactly what the funder was hoping to prove

75% of 'positive' studies get published vs 25% of 'negative'

Mainstream News, Medical
Magazines and Medical
Organizations receive large amounts
of funding from Big Pharma

Therapeutic peptides

are a relatively new class of pharmaceutical agents typically composed of molecules bound by peptide bonds (similar to protein bonds) in an organized array of less than 50 elements.

Their discovery amongst what was considered 'waste' or 'metabolites' from the breakdown of the miracle human bodies natural processes has and will change medicine in dramatic and beneficial ways.

Table 1. Peptide drugs approved since 2000, with their targets and indications					indications		
Target name	Peptide name	First approval	Approved indication(s)	Clinical trial phase	Peptide name	Indication(s) for investigation	
GLP-1 receptor	Exenatide ⁴⁶²	2005	Indicated for Type 2 Diabetes Mellitus	IV	Avexitide ⁵⁰⁰	Hypoglycemia	
	Liraglutide ⁴⁶³	2009			Calcitonin gene-related	Migraine	
	Lixisenatide ⁴⁶⁴	2013			peptide ⁵⁰¹	migranic	
	Albiglutide ⁴⁶⁵	2014			Corticorelin ⁵⁰²	Brain swelling; brain	
	Dulaglutide ⁴⁶⁶	2014			Leptin ⁵⁰³	neoplasms Lipodystrophy; obesity	
	Semaglutide ⁴⁶⁷	2017			Thymalfasin 504	Liver Cirrhosis; Sepsis	
GLP-2 receptor	Teduglutide ⁴⁶⁸	2012	Treatment of Short bowel syndrome and malabsorption	III	Aclerastide 505,506	Diabetic foot ulcers	
GC-C receptor	Linaclotide ⁴⁶⁹	2012	Treatment of irritable bowel syndrome (IBS) with constipation and chronic idiopathic constipation		Albusomatropin ⁵⁰⁷ Anamorelin ⁵⁰⁸	Growth hormone deficience Cachexia; lung cancer non	
Calcitonin receptor	Pramlintide ⁴⁷⁰	2005	Treatment of Type 1 and Type 2 Diabetes Mellitus		G17DT ⁵⁰⁹	small cell cancer	
GnRH receptor	Abarelix ⁴⁷¹	2003	Treatment of advanced prostate cancer		Insulin peglispro ⁵¹⁰	Various forms of cancer Diabetes mellitus	
750	Degarelix ⁴⁷²	2008			Lenomorelin ⁵¹¹	Malignancies	
Binding to active site of the 20S	Carfilzomib ⁴⁷³	2012	Treatment of multiple myeloma		Selepressin ⁵¹²	Shock; septic	
proteasome NOD2 protein	Mifamurtide ⁴⁷⁴	2009	Treatment of high-grade, resectable, non-metastatic		Somapacitan ⁵¹³	Adult growth hormone deficiency	
	Wild Half Gae	2005	osteosarcoma		Taspoglutide ⁵¹⁴	Type 2 diabetes mellitus	
VIP1 receptor	Aviptadil ⁴⁷⁵	2000	Treatment of erectile dysfunction		Thymosin beta-4 ⁵¹⁵	Dry eye syndrome	
OT receptor	Atosiban ⁴⁷⁶	2000	Indicated for use in delaying imminent pre-term birth		Tirzepatide ⁵¹⁶ Ularitide ⁵¹⁷	Type 2 diabetes mellitus Decompensated heart fail	
	Carbetocin 476	2001	Used for postpartum hemorrhage		Vapreotide ⁵¹⁸	Gastric varices; oesophage	
TRH receptor	Taltirelin ⁴⁷⁷	2000	Spinocerebellar degeneration			haemorrhage; portal	
MC receptors	Bremelanotide ⁴⁷⁸	2019	Indicated for hypoactive sexual desire disorder			hypertension; esophageal varices	
PTH1 receptor	Teriparatide ⁴⁷⁹	2002	Treatment of osteoporosis		Vosoritide ⁵¹⁹	Achondroplasia	
	Abaloparatide ⁴⁸⁰	2017	100 D00 000\$0000		Zoptarelin doxorubicin ⁵²⁰	Endometrial cancer; prostate cancer	
Guanylate cyclase C	Plecanatide ⁴⁸¹	2017	Treatment of chronic idiopathic constipation	li l	Angiotensin 1-7 ⁵²¹	Miscellaneous Peripheral	
NPR-A	Nesiritide ⁴⁸²	2001	Treatment of acute decompensated heart failure			Blood Cell Abnormalities	
AT ₁ receptor	Angiotensin II ⁴⁸³	2017	Indicated for sepsis and septic Shock		Bombesin ⁵²²	Prostate cancer	
Beta2-receptor	Icatibant ⁴⁸⁴	2008	Approved for use in acute attacks of hereditary angioedema		Cenderitide ³¹⁰ Deslorelin ⁵²³	Heart failure Puberty; precocious	
gp41	Enfuvirtide ⁴⁸⁵	2003	Used in combination therapy for the treatment of HIV-1		Gastric inhibitory	Type 2 diabetes mellitus	
GHRH receptor	Tesamorelin ⁴⁸⁶	2010	Reduction of HIV lipodystrophy		polypeptide ⁵²⁴		
N-type calcium channels	Ziconotide ⁴⁸⁷	2004	Management of severe chronic pain		MK-3207 ⁵²⁵	Migraine	
Thrombopoietin receptor	Romiplostim ⁴⁸⁸	2008	Treatment of chronic immune thrombocytopenic purpura		Olcegepant ⁵²⁶ Pancreatic	Migraine Disorders Type 1 diabetes	
Human erythropoietin receptor	Peginesatide ⁴⁸⁹	2012	Treatment of anemia associated with chronic kidney disease		Polypeptide ⁵²⁷	Type 1 diabetes	
Pulmonary surfactant	Lucinactant ⁴⁹⁰	2012	Prevention of respiratory distress syndrome		Peptide YY (3-36) ⁵²⁸	Metabolic disease; obesity	
CaSR	Etelcalcetide ⁴⁹¹	2016	Indicated for secondary hyperparathyroidism		Pirnabine ⁵²⁹	Chronic idiopathic constipation	
MC1 receptor	Afamelanotide ⁴⁹²	2014	Prevention of phototoxicity		Somatoprim ⁵³⁰	Acromegaly	
Somatostatin receptors	Pasireotide ⁴⁹³	2012	Treatment of Cushing's disease		Somatropin pegol ⁵³¹	Growth hormone deficien-	
	Lutetium Lu 177 dotatate ^{494,495}	2018	Treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors		Thyrotropin ⁵³²	Benign nontoxic and toxic goiter; goiter; nodular	
	Edotreotide gallium Ga-68 ^{496,497}	2019	Indicated for diagnose somatostatin receptor positive neuroendocrine tumors		TT-232 ⁵³³ BPI-3016 ⁵³⁴	Renal cell adenocarcinom Type 2 diabetes mellitus	
Melanocortin-4 receptor	Setmelanotide 498,499	2020	Indicated for chronic weight management of obesity		NBI-6024 ⁵³⁵ Many more	Type 1 diabetes mellitus	


Good to Know

Most of the peptides we are 'discovering' are **natural functions** of the human body - this is important!
Critical! It is the power of the inhibitors of normal bodily functions that play a huge role in resistance and rejection of these treatments!



There are NO silver bullets!

Peptides are amazing in their realm. Let's see why they may not work optimally and what we can do to increase their potency and scope.





Best Success: Strong Attraction, Strong Repulsion = Survival and Optimization

Influence:

- 1. Self
- 2. Environment
- 3. Other Organisms

Key: One Cell Influences MANY!





Chemical

Best Success:
Strong Attraction,
Strong Repulsion
= Survival and
Optimization


Influence:


- 1. Self
- 2. Environment
- 3. Other Organisms

Purpose: Attract Bennies, Repel Enemies!

Mechanical

Key: Many Cells Influence Organism!





Why is this important?

When Single Celled Organisms
Invade Multi-Celled Organisms
the SCO Has a <u>Threshold</u>
Reaction Advantage

Influence:

- 1. Self Mobility Location
 - a. Anatomical Recesses
- 2. Environment Camo
 - a. Biofilms
 - b. Membranes
- 3. Other Organisms Host
 - a. Epigenetics

In the right environment, the invader WILL run the metabolism, energy and function of the host!


The environment of which I speak is called: DISEASE.

MULTIPLE studies across many DECADES old have proven that **chronic Viral**, **Fungal and Parasitic** infections are a MAJOR source of disease:

- CAD MI HTN
- CVD Strokes
- Metabolic Dz DM, Obesity, etc.

Another often overlooked element of these disease processes is what these chronic infections do to our systemic microbiome. FYI: They manipulate IT just as they do US!

What creates optimal environments for disease?



7 Triggers of ALL Disease:

- 1. Congenital Dz vs Predisposition
- 2. Toxins
 - a. Metals InOrganic
 - b. HydroCarbon Organic
- 3. Infection
 - a. Viral
 - b. Fungal
 - c. Parasites
 - d. Bacterial
- 4. Trauma Physical Accidents
- 5. Nutrition Deficiencies (97%)
- 6. Stress Emotional Infections
- 7. Energy EMF's Etc.







A Common Scenario:


- 1. Weakened Organism:
 - a. Congenital Predisposition
 - b. **Nutritional** Deficiency
 - c. **Toxic** Intake
 - d. Trauma
 - e. Stress
 - f. EMF's
- 2. Enter **Infection** Finds Location
 - a. Camo
 - b. Biofilms
- 3. Infections use:
 - a. Toxins NeuroToxins Collagenase
 - b. Biofilms
 - c. Epigenetics DNA




Well, Duh!

Rapid Fire Facts:

- VFP Infections epigenetically cap and alter our DNA expression (methylation)
- VFP's alter our immune function (often first is fever)
- VFP's set up biofilms whenever and wherever they can:
 - Dental Plaques Tarter
 - Arterial Plaques
 - Gallstones
 - Appendicoliths
 - The worst is when they set up in the Peritoneal Anatomical Recesses in the abdomen and pelvis




Peritoneal Abdominal Anatomical Recesses



BIOFILM FACTS:

- Protect against Antibiotics Natural or synthetic
- Protect against energy therapies -
 - Snot is a great insulator
- Allow MULTIPLE organisms to work synergistically
 - Parasites release NeuroToxins and Collagenase
 - Fungi release NeuroToxins and Collagenase
- Pathologic bacteria often enter the conglomeration
- The Community uses trapped toxic metals and hydrocarbons as
 enzymatic catalysts. Calcium, Lead & Mercury are commonly used
- Acidic which further toxifies the conglomerate community
- Hypoxic major epigenetic microbiome alteration and influence
- EXTREME TOXICITY!





Let's Bring This Full Circle

Peptide Purpose	Pathogenic Block	Result		
GLP-1 - Metabolic Adaptations	Epigenetic block to metabolic pathways NeuroToxins = Sluggish 2nd brain	Diminished to zero response May only see side effects & zero benefit		
BCP-157 - Stem cell Activation, Collagen formation/repair, etc	Epigenetic blocks Collagenase - Brakes faster than repair	Diminished to zero response		
CHK-Cu - Epigenetic Stem Cell Activation	Epigenetic Blocks Collagenase	Wrinkles, etc.		

Most if not all of our peptides need:

- 1. Functional Tissue
- 2. Zero Toxins
- 3. Time



Maximize Effectiveness:

7 Triggers of ALL Disease:

- 1. Congenital -
- 2. Toxins -
- 3. Infection

- 4. Trauma -
- 5. Nutrition Deficiencies -
- 6. Stress -
- 7. Energy -

Supplements
Consider Meds (NSAIDS)
Aggressive Detox


- a. Anti-Viral
- b. Attack Biofilms
 - i. Anti-Fungal
 - ii. Parasitics
 - iii. ABX

RenuO2 or Prolozone

Supplement

Stacked Stress Tx

PEMF, SoundWave, others



Tempered and Threshold
Reactions will be different for each and every patient!

- Congenital Predisposition
- Trauma
- Exposures to
 Toxins/Infections
- Nutrition Availability
- **EMF** Exposure

Of Note!

Fungal and Parasite Infections are chronic, camouflaged and very difficult to discover.

Luse:


Detailed Intake Form
Energy Testing (SCENAR Tech)
Physical Examination
Lab Testing (Which is still lacking)



Findings:

All patients have chronic HS Viruses 8-16 Varieties of Fungal Infections 25-35 Varieties of Parasites

Discovery Continuum



Summary

Tempered and Threshold Reactions will be different for each and every patient!

- Congenital Predisposition
- Trauma History
- Exposures to **Toxins/Infections**
- Nutrition Availability
- EMF Exposure History
 - Stay Vigilant!
 - Stand strong for your patients Keep Optimizing your care
 - Seek higher ground with morals and ethics!
 - Walson's Law: The Flow of Information and Ideas = Success and \$\$

This is the only chance we have against the big boys of medicine.

You got this!







Research:

- http://peptides.org
- 2. https://www.cochrane-handbook.org/
- 3. https://www.medicalnewstoday.com/articles/326701
- 4. Wang, Lei (2022 Signal Transduction & Targeted Therapy 7:48) Therapeutic Peptides: Current Applications and Future Directions
- 5. Derby, Charles D (2011 Integr Comp Biol. Nov;51(5):771-80. doi: 10.1093/icb/icr063) The neuroechology of chemical defenses
- 6. Zhao, Yuhai (2022 Int J Mol Sci. Oct 21;23(20):12671) Lipopolysaccharides (LPS's) as potent neurotoxic glycolipids in alzheimer's disease (AD)
- 7. Yang, Junkui (2007 Appl Microbiol Biotechnol. May;75(1):21-31) Extracellular enzymes and the pathogenesis of nematophagous fungi
- 8. Munoz, M L (1982 J Exp Med. Jan 1;155(1):42-51) The collagenase of Entamoeba histolytica
- 9. http://foundationalmedicine.com
- 10. https://www.khanacademy.org/science/ap-biology/cell-communication-and-cell-cycle/cell-communication/a/introduction-to-cell-signaling
- 11. <a href="https://bio.libretexts.org/Bookshelves/Introductory_and_General_Biology/General_Biology_1e_(OpenStax)/2%3A_The_Cell/09%3A_Cell_Communication/9.4%3A_Signaling_in_Single-Celled_Organisms
- 12. https://www.nature.com/scitable/topic/cell-communication-14122659/
- 13. https://www.khanacademy.org/science/ap-biology/cell-communication-and-cell-cycle/cell-communication/a/cell-cell-signaling-in-unicellular-organisms
- 14. Yang, Jinkui (2013 Appl Microbiol Biotechnol. Aug;97(16):7081-95.) Nematicidal enzymes from microorganisms and their applications
- 15. Nordwig, Arnold (1971 Advances in Enzymology and Related Areas of Molecular Biology Vol 34. Jan 1971 Ch4) Collagenolytic Enzymes
- 16. Schirzad, Mahdieh (2018 Artif Cells Nanomed Biotechnol. Feb 27 1051-1961) Anti-elastase and anti-collagenase potential of Lactobacilli exopolysaccharides on human fibroblast
- 17. Albuquerque Wanderley, Maria Carolina de (2017 Braz J Microbiol Jan-Mar;48(1):13-24.) Collagenolytic enzymes produced by fungi: a systematic review
- 18. Jorgensen, Anders Bech (2023 0 Int J Colorectal Dis. Dec 1;38(1):275.) Collagenase-producing bacteria are common in anastomotic leakage after colorectal surgery: a systematic review
- 19. Richardson, Johathan P, (2019 Semin Cell Dev Biol. May:89:58-70) Candida innate immunity at the mucosa
- 20. Papakonstantinau, A (2022 Cancer Treat Rev. Dec;111) The conundrum of breast cancer and microbiome A comprehensive review of the current evidence
- 21. Bordon, Yvonne (2002 Nat Rev Immunol. Sep;22(9):532-533) Fungus hijacks TLR4 to build a type 2 immune niche
- 22. https://www.nature.com/scitable/topic/cell-communication-14122659/
- 23. https://chempedia.info/info/tempering_reactions/
- 24. https://en.wikipedia.org/wiki/Threshold_energy
- 25. Williams, Thomas J (2020 Curr Opin Microbiol Dec:58:130-137) Immunotherapeutic approaches for fungal infections
- 26. Schirmer, Melanie (2016 Cell Nov 3;167(4):1125-1136.e8) Linking the Human Gut Microbiome to Inflammatory Cytokine Production Capacity
- 27. French, Peter W (2019 Neurotox Res. May;35(4):969-980) Fungal Neurotoxins and Sporadic Amyotrophic Lateral Sclerosis
- 28. Ulger, Taha Gokmen (2020 Toxicon Oct 15:185:104-113) Genotoxic effects of mycotoxins